A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression



Status:Recruiting
Conditions:Depression, Depression, Major Depression Disorder (MDD)
Therapuetic Areas:Psychiatry / Psychology, Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - 64
Updated:3/13/2019
Start Date:July 16, 2018
End Date:May 13, 2020
Contact:Study Contact
Email:JNJ.CT@sylogent.com
Phone:844-434-4210

Use our guide to learn which trials are right for you!

A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ-67953964 in Subjects With Major Depressive Disorder

The purpose of this study is to evaluate the efficacy of JNJ-67953964 compared to placebo
when administered as adjunctive treatment in participants with Major Depressive Disorder
(MDD) partially responsive to selective serotonin reuptake inhibitor/
serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) treatment in terms of reduction of
symptoms of depression, as assessed by the change from baseline on the Montgomery Asberg
Depression Rating Scale (MADRS) in non-responders during the placebo lead-in period.


Inclusion Criteria:

- Have a Body Mass Index (BMI) between 18 and 35 kilogram per meter square (kg/m^2)
inclusive (BMI = weight/height^2)

- Participants must be medically stable based on clinical laboratory tests, medical
history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening and
baseline

- Participants must have a primary Diagnostic and Statistical Manual of Mental Disorders
5th edition (DSM-5) diagnosis of Major Depressive Disorder (MDD)

1. The current episode should be less than 18 months

2. Participants should be currently treated with an SSRI or SNRI at an adequate dose
and for at least 6 weeks but no more than 12 months

3. Have a Montgomery-Asberg Depression Rating Scale (MADRS) total score greater than
or equal to (>=) 25 at screening

- A woman of childbearing potential must have a negative serum pregnancy test at
screening and a negative urine pregnancy test before the first dose

Exclusion Criteria:

- History of documented gastric disease (including documented peptic ulcer disease,
gastritis, upper gastrointestinal [GI] bleeding, esophagitis, or any GI precancerous
condition), current clinically evident GI complaints

- Chronic use of a proton pump inhibitors (PPIs). History of incidental use of PPIs is
allowed but should have been stopped at least 4 weeks before screening. A history of
chronic nonsteroidal anti-inflammatory drug (NSAID) or aspirin use. (Low dose aspirin
for example in cardiovascular disease prevention is allowed)

- Has a history of alcohol use disorder within the past year

- Has failed (no more than 25 percent [%] response on Antidepressant Treatment History
Questionnaire [ATRQ]) three or more antidepressant treatments including the current
Selective serotonin reuptake inhibitor/ serotonin-norepinephrine reuptake inhibitor
(SSRI/SNRI) and including the current and all previous depressive episodes despite an
adequate dose (per ATRQ) and duration (at least 6 weeks)

- Has signs or symptoms of Cushing's Disease, Addison's Disease, primary amenorrhea, or
other evidence of significant medical disorders of the hypothalamus pituitary adrenal
(HPA) axis

- Participant has received an investigational drug (including investigational vaccines)
or used an invasive investigational medical device within 3 months before the planned
first dose of study drug or has participated in any interventional clinical studies on
MDD in the previous 1 year or is currently enrolled in an interventional study

- Has one or more of the following diagnoses:

1. A primary DSM (5th edition) diagnosis of generalized anxiety disorder (GAD),
panic disorder, obsessive compulsive disorder (OCD), posttraumatic stress
disorder (PTSD). Participants with comorbid GAD, social anxiety disorder (SAD),
or panic disorder for whom MDD is considered the primary diagnosis are not
excluded

2. A current diagnosis or diagnosis in the past 1 year of psychotic disorder, MDD
with psychosis, anorexia nervosa or bulimia nervosa, chronic fatigue syndrome,
bipolar disorder (BD), mental retardation, antisocial or borderline personality
disorder, autism spectrum disorder

- Has a current or recent history of clinically significant suicidal ideation within the
past 6 months, corresponding to a score of 4 (active suicidal ideation with some
intent to act, without specific plan) or 5 (active suicidal ideation with specific
plan and intent) for ideation on the Colombia suicide severity rating scale (C-SSRS),
or a history of suicidal behavior within the past 1 year

- Ongoing psychological treatments (example, Cognitive Behavior Therapy, Interpersonal
Psychotherapy, Psychodynamic Psychotherapy, etcetera [etc.]), initiated within 1 month
prior to the screening phase. A participant who has been receiving ongoing
psychological treatment for a period of greater than 1 month from the screening visit
is eligible, if the investigator deems the psychological treatment to be of stable
duration and frequency

- Participant has a history of substance use disorder according to DSM-5 criteria,
except nicotine or caffeine, within 6 months before screening. Mild cases can be
reviewed on a case by case basis. Participants who have completed a treatment for
(alcohol) addiction more than 1 year prior to first dose administration, may be
included if the risk of relapse is considered minimal, total duration of alcohol use
disorder was less than a year, and no significant abnormalities are shown in clinical
laboratory or other pre-dose safety assessments

- Participant has used:

a) Monoamine oxidase inhibitors (MAOIs) within 12 weeks before screening b) St. John's
wort, ephedra, ginkgo, ginseng, or kava within 2 weeks before screening c)
Antipsychotic drugs (D2-antagonists), lithium or other mood stabilizers within 2 weeks
before screening d) Opioids within 2 weeks before screening e) Psychostimulants such
as methylphenidate or dextroamphetamine within 2 weeks before screening f)
Psychotropics with antidepressant effects such as atomoxetine or thyroid
supplementation, in addition to their SSRI or SNRI treatment within 2 weeks before
screening g) Any hypnotics including but not limited to: i. Benzodiazepines ii.
Sedating antihistamines, including chronic use of diphenhydramine iii. Continuous use
of zolpidem, zoplicon, eszopiclone and ramelteon iv. S-adenosyl methionine (SAMe) v.
Melatonin, agomelatine h) NSAID and aspirin

- Participant is unable to stop the following medication from the baseline visit (Visit
2) and throughout the study (tapering during screening period allowed):

a) Any hypnotics including but not limited to: i. Benzodiazepines ii. Sedating
antihistamines, including chronic use of diphenhydramine iii. Continuous use of
zolpidem, zoplicon, eszopiclone and ramelteon. Note: Nonbenzodiazepines sleep aids
(including: zolpidem, zaleplon, and eszopliclone) are allowed on an as needed (PRN)
basis during the study but NOT within 24 hours before being in the clinic and not more
than 2 nights in a row iv. S-adenosyl methionine (SAMe) v. Melatonin, agomelatine b)
NSAID and aspirin

- Has received any prior treatment with electroconvulsive therapy, vagal nerve
stimulation, or a deep brain stimulation device or treatment with ketamine or
esketamine for MDD
We found this trial at
31
sites
Orange, California 92868
?
mi
from
Orange, CA
Click here to add this to my saved trials
Allentown, Pennsylvania 18104
?
mi
from
Allentown, PA
Click here to add this to my saved trials
2150 Peachford Road
Atlanta, Georgia 30338
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Brooklyn, New York 11229
?
mi
from
Brooklyn, NY
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Chicago, Illinois 60634
?
mi
from
Chicago, IL
Click here to add this to my saved trials
281 W. Lane Ave
Columbus, Ohio 43210
(614) 292-6446
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
?
mi
from
Dayton, OH
Click here to add this to my saved trials
Glendale, California 91204
?
mi
from
Glendale, CA
Click here to add this to my saved trials
Hickory, North Carolina 28601
?
mi
from
Hickory, NC
Click here to add this to my saved trials
Irvine, California 92614
?
mi
from
Irvine, CA
Click here to add this to my saved trials
Lake Charles, Louisiana 70601
?
mi
from
Lake Charles, LA
Click here to add this to my saved trials
Lansdale, Pennsylvania 19446
?
mi
from
Lansdale, PA
Click here to add this to my saved trials
Little Rock, Arkansas 72211
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Memphis, Tennessee 38119
?
mi
from
Memphis, TN
Click here to add this to my saved trials
1801 Coral Way
Miami, Florida 33133
?
mi
from
Miami, FL
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73112
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73103
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Orlando, Florida 32803
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Pikesville, Maryland 21208
?
mi
from
Pikesville, MD
Click here to add this to my saved trials
Princeton, New Jersey 08540
?
mi
from
Princeton, NJ
Click here to add this to my saved trials
11748 Magnolia Avenue
Riverside, California 92503
?
mi
from
Riverside, CA
Click here to add this to my saved trials
San Marcos, California 92078
?
mi
from
San Marcos, CA
Click here to add this to my saved trials
Skokie, Illinois 60076
?
mi
from
Skokie, IL
Click here to add this to my saved trials
4349 Hylan Boulevard
Staten Island, New York 10312
?
mi
from
Staten Island, NY
Click here to add this to my saved trials
Tampa, Florida 33609
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Tampa, Florida
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Tucson, Arizona 85704
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
Upland, California 91786
?
mi
from
Upland, CA
Click here to add this to my saved trials
West Jordan, Utah 84088
?
mi
from
West Jordan, UT
Click here to add this to my saved trials
55 N Lake Ave
Worcester, Massachusetts 01655
(508) 856-8989
Univ of Massachusetts Med School As the commonwealth's only public medical school, we take seriously...
?
mi
from
Worcester, MA
Click here to add this to my saved trials